U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07413835) titled 'Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)' on Feb. 03.
Brief Summary: This is an open label, single arm study, to evaluate the safety , tolerability and preliminary efficacy of HN2302 for refractory myasthenia gravis.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Refractory Myasthenia Gravis
Intervention:
DRUG: HN2302 Injection
Patients will be administrated with specified dose on specified days at a lower dose level and escalated to safe and effective dose levels.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: The Affiliated Hospital of Xuzhou Medical University
Published by ...